TICKERNERD
Menu
LHLHHealthcare · Diagnostics & Research

LH Stock Forecast: Labcorp Holdings, Inc. Price Predictions for 2026-2027

Last close, 6 Aug 2026
$317
+0.81% on the day

The 18 Wall Street analysts covering Labcorp Holdings, Inc. hold a median 12-month price target of $345 — +9.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 88 of 100 as at 6 Aug 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$25.3B
Ticker Nerd rank
88 / 100
Median analyst target
$345
Analysts covering
18
Total return, dividends reinvested
1W
+0.3%
1M
+11.3%
YTD
+26.8%
1Y
+22.6%
From 52W high
0.0%
From 52W low
+29.3%
$245
$317
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

LH stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Labcorp Holdings, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 6 Aug 2026
88 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
96
Revisions
90
Quality
74
Growth
74
Issuance
70
Value
67
Momentum
67
Accruals
55
Size
8

Volatility (96): The share price has been relatively steady.

Accruals (55): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Size (8): Larger than most of the companies we track — more scrutinised, less often mispriced.

The rank is the raw material. Whether the rules would actually own Labcorp Holdings, Inc. — and when they’d sell — is the membership.

Wall Street

LH stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on LH, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$250$300$350$400Oct 25Jan 26Apr 26Jul 26LHHigh $385Median $345Low $270

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says18 analysts
13 Buy5 Hold0 Sell
Low $270Median $345High $385

The green dot is the last close — the median target sits +9.0% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 7 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
4 Aug 2026Piper SandlerMaintainsNeutral$300 → $309
3 Aug 2026JP MorganMaintainsOverweight$330 → $360
31 July 2026BarclaysMaintainsEqual-Weight$290 → $320
31 July 2026Morgan StanleyMaintainsOverweight$308 → $338
31 July 2026Truist SecuritiesMaintainsBuy$320 → $350
13 July 2026B of A SecuritiesMaintainsBuy—
13 July 2026B of A SecuritiesMaintainsBuy$300 → $320
13 July 2026BairdMaintainsOutperform$335 → $338
13 July 2026BairdMaintainsOutperform—
8 Apr 2026Evercore ISI GroupMaintainsOutperform—
24 Feb 2026Piper SandlerMaintainsNeutral—
18 Feb 2026BairdMaintainsOutperform—
18 Feb 2026JP MorganMaintainsOverweight—
6 Feb 2026JP MorganMaintainsOverweight—
7 Nov 2025JP MorganMaintainsOverweight—
29 Oct 2025UBSMaintainsBuy—
17 Oct 2025MizuhoMaintainsOutperform—
17 Oct 2025UBSMaintainsBuy—
3 Oct 2025Evercore ISI GroupMaintainsOutperform—
2 Oct 2025BarclaysMaintainsEqual-Weight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Estimates

LH analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
+2.1%
Analysts raising
1
Analysts cutting
1
Fundamentals

Labcorp Holdings, Inc. (LH) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
26.0×

Cheaper than 31% of US stocks

Price / sales
1.8×

Cheaper than 57% of US stocks

Price / book
2.9×

Cheaper than 35% of US stocks

EV / EBITDA
13.6×

Cheaper than 28% of US stocks

Growth & margins
Revenue growth (YoY)
5.8%

Higher than 43% of US stocks

Earnings growth (YoY)
25.6%

Higher than 65% of US stocks

Gross margin
28.7%

Higher than 34% of US stocks

Operating margin
12.2%

Higher than 70% of US stocks

Net margin
7.0%

Higher than 64% of US stocks

Returns & dividend
Return on equity
11.7%

Higher than 68% of US stocks

Return on assets
5.5%

Higher than 80% of US stocks

Dividend yield
0.9%

Higher than 21% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

LH vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelDiagnostics & Research
CompanyMarket capTKN rank
LHLabcorp Holdings, Inc.$25.3B
88
DGXQuest Diagnostics, Inc.$26.5B
95
MTDMettler-Toledo International, Inc.$29.0B
92
ILMNIllumina, Inc.$29.8B
96
GHGuardant Health, Inc.$20.4B
43
NTRANatera, Inc.$36.6B
79
IQVIQVIA Holdings, Inc.$38.3B
91
Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. LH appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

News

Latest LH news & analysis

Labcorp Stock Jumps 14% in a Month as Growth Meets Rich Valuation

Zacks Investment Research · 7 Aug 2026positive

Labcorp (LH) shares rose 14% over the past month, driven by stronger earnings and margin gains, while the stock's valuation now sits above its five-year median. The price increase reflects a combination of growth momentum and an increasingly rich valuation.

Why it matters — A LH watcher would care because the stock's rapid climb signals improving financial performance even as its elevated valuation relative to historical levels raises the question of how much growth is already priced in.

Here's Why Labcorp Holdings (LH) is a Strong Value Stock

Zacks Investment Research · 4 Aug 2026positive

A Zacks Investment Research piece highlights Labcorp Holdings (LH) as a strong value stock, referencing the Zacks Style Scores system as a way to identify market-beating stocks. The article suggests LH scores well on value-related criteria within that framework.

Why it matters — A favorable mention by Zacks raises LH's visibility among value-focused investors tracking the stock.

Labcorp Launches FDA-Approved PTEN Companion Diagnostic for Prostate Cancer

PRNewsWire · 4 Aug 2026positive

Labcorp announced the nationwide availability of Roche's VENTANA PTEN (SP218) RxDx Assay, the first FDA-approved immunohistochemistry companion diagnostic that determines PTEN protein loss in tumors of patients with prostate adenocarcinoma. The test identifies patients who may be eligible for combination treatment with TRUQAP (capivasertib).

Why it matters — A Labcorp watcher would care because this marks the company's launch of a first-of-its-kind FDA-approved companion diagnostic, expanding its prostate cancer testing offerings.

Labcorp Q2 Earnings Call Highlights

MarketBeat · 31 July 2026positive

Labcorp reported second-quarter 2026 revenue growth, margin expansion, and higher adjusted earnings. The company also raised the midpoint of its full-year revenue and adjusted EPS guidance.

Why it matters — The guidance raise signals confidence in continued operational improvement, which is relevant to LH investors tracking the company's financial trajectory.

Labcorp Holdings Inc. (LH) Q2 2026 Earnings Call Transcript

Seeking Alpha · 30 July 2026neutral

Labcorp Holdings Inc. held its Q2 2026 earnings call, with a transcript of the event published on Seeking Alpha.

Why it matters — A LH watcher would care because the earnings-call transcript provides management's detailed discussion of quarterly performance and outlook.

FAQ

Frequently asked questions about LH stock

What is the LH stock price forecast for 2026-2027?

The 18 Wall Street analysts covering Labcorp Holdings, Inc. have a median 12-month price target of $345, with estimates ranging from $270 to $385. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is LH stock a buy right now?

Of the 18 analysts covering Labcorp Holdings, Inc., 13 rate it a Buy, 5 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Labcorp Holdings, Inc. 88 out of 100 across roughly 4,600 US stocks as at 6 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank LH?

As at 6 Aug 2026, Labcorp Holdings, Inc. ranks 88 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (96 of 100).

Will LH stock go up?

No one can know that. What the data says: the median 12-month target from 18 analysts implies +9.0% from the last close, and Ticker Nerd's factor model ranks Labcorp Holdings, Inc. 88 out of 100 as at 6 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the LH stock forecast for 2030?

No analyst covering Labcorp Holdings, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for LH are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $270 to $385 over the next 12 months.

How has LH stock performed over the past year?

Labcorp Holdings, Inc. returned +22.6% over the 12 months to 6 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Labcorp Holdings, Inc. do?

Labcorp Holdings Inc. is a healthcare diagnostics and laboratory services company that supports physicians, hospitals, pharmaceutical companies, researchers, and patients with clinical testing and scientific insights.

What is the latest news on LH?

The most recent item we track (Zacks Investment Research, 7 Aug 2026): "Labcorp Stock Jumps 14% in a Month as Growth Meets Rich Valuation". Labcorp (LH) shares rose 14% over the past month, driven by stronger earnings and margin gains, while the stock's valuation now sits above its five-year median. The price increase reflects a combination of growth momentum and an increasingly rich valuation.

Company

About Labcorp Holdings, Inc.

Labcorp Holdings Inc. is a healthcare diagnostics and laboratory services company that supports physicians, hospitals, pharmaceutical companies, researchers, and patients with clinical testing and scientific insights. Labcorp Holdings Inc. operates through its Diagnostics Laboratories and Biopharma Laboratory Services segments, providing a broad portfolio of routine blood and urine tests as well as specialized services in oncology, genomics, and drug development support. The company maintains an extensive network of patient-service centers and laboratory operations that help deliver testing access, sample processing, and analytical capabilities across the healthcare system. Labcorp Holdings Inc. plays an important role in clinical decision-making, disease detection, and research support by translating laboratory data into information used in patient care and life sciences workflows.

CEO Mr. Adam H. Schechter · 71,000 employees · United States · https://www.labcorp.com